{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+or+Refractory+Multiple+Myeloma+%28MM%29", "query": { "condition": "Relapsed or Refractory Multiple Myeloma (MM)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 53, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+or+Refractory+Multiple+Myeloma+%28MM%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-02T06:07:52.614Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00743288", "title": "Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Melphalan", "type": "DRUG" }, { "name": "Panobinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2008-07", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2014-05-08", "last_synced_at": "2026-10-02T06:07:52.614Z", "location_count": 4, "location_summary": "Bakersfield, California • West Hollywood, California • Denver, Colorado + 1 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "West Hollywood", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00743288" }, { "nct_id": "NCT03567616", "title": "A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2018-10-18", "completion_date": "2020-06-18", "has_results": true, "last_update_posted_date": "2021-06-30", "last_synced_at": "2026-10-02T06:07:52.614Z", "location_count": 5, "location_summary": "Columbus, Georgia • Fairway, Kansas • St Louis, Missouri + 2 more", "locations": [ { "city": "Columbus", "state": "Georgia" }, { "city": "Fairway", "state": "Kansas" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03567616" }, { "nct_id": "NCT06627751", "title": "Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Extramedullary Disease in Multiple Myeloma", "Recurrent Multiple Myeloma", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "Mezigdomide", "type": "BIOLOGICAL" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Echocardiography", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Computed Tomography Assisted Biopsy", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2025-05-01", "completion_date": "2030-05-01", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-10-02T06:07:52.614Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06627751" }, { "nct_id": "NCT04975997", "title": "Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Iberdomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 939, "start_date": "2022-06-23", "completion_date": "2032-06-25", "has_results": false, "last_update_posted_date": "2026-04-03", "last_synced_at": "2026-10-02T06:07:52.614Z", "location_count": 43, "location_summary": "Hot Springs, Arkansas • Cerritos, California • Fountain Valley, California + 38 more", "locations": [ { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Cerritos", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04975997" }, { "nct_id": "NCT04883242", "title": "Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Multiple Myeloma", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Isatuximab", "type": "BIOLOGICAL" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Skeletal Survey X-Ray", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2021-07-29", "completion_date": "2031-12-31", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-10-02T06:07:52.614Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04883242" }, { "nct_id": "NCT01575925", "title": "Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma", "Renal Impairment" ], "interventions": [ { "name": "4 mg Oral POM + 40 mg Oral DEX", "type": "DRUG" }, { "name": "2 mg Oral POM + 40 mg Oral DEX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2012-06-01", "completion_date": "2018-08-07", "has_results": false, "last_update_posted_date": "2022-11-04", "last_synced_at": "2026-10-02T06:07:52.614Z", "location_count": 7, "location_summary": "Denver, Colorado • Atlanta, Georgia • Harvey, Illinois + 4 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Harvey", "state": "Illinois" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01575925" }, { "nct_id": "NCT00710528", "title": "Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia (CLL)", "Lymphoma, Non-Hodgkin (NHL)", "Acute Myeloid Leukemia (AML)", "Multiple Myeloma (MM)" ], "interventions": [ { "name": "CAL-101", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 192, "start_date": "2008-06", "completion_date": "2012-08", "has_results": false, "last_update_posted_date": "2012-08-31", "last_synced_at": "2026-10-02T06:07:52.614Z", "location_count": 9, "location_summary": "Palo Alto, California • Baltimore, Maryland • Boston, Massachusetts + 6 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00710528" }, { "nct_id": "NCT03465540", "title": "Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma", "Acute Myeloid Leukemia", "Non-Hodgkins Lymphoma", "Myelodysplastic Syndrome", "AML", "MDS", "NHL" ], "interventions": [ { "name": "AMG 397", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 24, "start_date": "2018-08-17", "completion_date": "2019-07-25", "has_results": true, "last_update_posted_date": "2023-04-12", "last_synced_at": "2026-10-02T06:07:52.614Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Jacksonville, Florida + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Westwood", "state": "Kansas" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03465540" }, { "nct_id": "NCT02658396", "title": "GO-203-2C + Bortezomib For Relapsed Or Refractory MM", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma", "Multiple Myeloma in Relapse", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "GO-203-2C", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": null, "completion_date": "2022-01", "has_results": false, "last_update_posted_date": "2017-07-05", "last_synced_at": "2026-10-02T06:07:52.614Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02658396" }, { "nct_id": "NCT07771803", "title": "A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "AML (Acute Myeloid Leukemia)", "Multiple Myeloma Refractory" ], "interventions": [ { "name": "Soursop tea", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Roger Strair", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2025-06-30", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-10-02T06:07:52.614Z", "location_count": 1, "location_summary": "Camden, New Jersey", "locations": [ { "city": "Camden", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT07771803" } ] }